Skip to main content
. 2020 Jun 18;12(6):1623. doi: 10.3390/cancers12061623

Figure 1.

Figure 1

Kaplan-Meier curves illustrate the time to castration-resistance (CR) progression among groups of de novo metastatic prostate cancer (mPCa) patients. (a) HLA-A*02:01+ vs HLA-A*02:01; (b) HLA-A*24:02+ vs HLA-A*24:02; (c) HLA-A*02:01+ HLA-A*24:02 vs HLA-A*24:02+ HLA-A*02:01. Shown are statistical differences and hazard ratios among the groups.